title: A selective decoy-doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect.
abstract: A novel selective decoy oligodeoxynucleotide (dODN)-doxorubicin (DOX) complex is reported for cancer theranostics. It eliminates the use of a ligand or carrier for targeted delivery and disassembles into therapeutic dODN and DOX upon encountering over-activated STAT3 in cancer cells. Hence, in situ STAT3 probing and synergistic anti-cancer effect are attained at the same time.
authors.affiliation: Department of Bio-Industrial Mechatronics Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd., Taipei 10617, Taiwan, Republic of China. chenlinchi@ntu.edu.tw.
authors.forename: Shao-Jen
authors.initials: SJ
authors.lastname: Wang
authors.forename: Yung-Te
authors.initials: YT
authors.lastname: Hou
authors.forename: Lin-Chi
authors.initials: LC
authors.lastname: Chen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004337:Drug Carriers / Q000737:chemistry; D005456:Fluorescent Dyes; D056945:Hep G2 Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry; D061986:MCF-7 Cells; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D050796:STAT3 Transcription Factor / Q000037:antagonists & inhibitors*; D000068936:Theranostic Nanomedicine
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D005456:Fluorescent Dyes; D008055:Lipids; C086724:Lipofectamine; D009838:Oligodeoxyribonucleotides; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D004317:Doxorubicin